The long-standing expectation that the global obesity drug market would reach $150 billion within the next decade is becoming less certain as prices for leading GLP-1 treatments from Novo Nordisk and Eli Lilly decline in the United States. Analysts say intensifying competition, the rise of cash-pay consumers, and the prospect of new drugs and generics […]